Compare iShares MSCI Malaysia ETF (EWM) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Malaysia ETF vs Mesoblast Limited — how do they compare? iShares MSCI Malaysia ETF trades at $26.66 (market cap $256.41M), while Mesoblast Limited trades at $14.29 (market cap $1.75B). The key difference: Mesoblast Limited is far larger — about 6.8× iShares MSCI Malaysia ETF's market cap, and iShares MSCI Malaysia ETF is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Malaysia ETF for 66 Days and Mesoblast Limited for 15 Days on average.
| EWM | MESO | |
|---|---|---|
Market Cap | $256.41M | $1.75B |
Volume | 111,962 | 239,027 |
Sector | Broad Market / Factor | Health |
52-Week High | $30.42 | $20.96 |
52-Week Low | $25.33 | $13.19 |
Typical Hold Time | 66 Days | 15 Days |
Enterprise Value | — | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWM stock trades at $26.66 with minimal daily movement (+0.19%). Technical indicators show conflicting signals with moving averages suggesting bearish pressure while oscillators indicate potential oversold conditions. The stock faces immediate resistance at $27 and support at $26. Recent news highlights regional environmental challenges affecting operations.
The stock presents a cautious outlook with mixed technical signals and limited fundamental data available. Near-term direction will depend on earnings results and management guidance. Key risks include operational disruptions from regional environmental issues and broader market volatility affecting small-cap stocks.
MESO trades at $14.29, up 2.51% today, amid bearish technical signals but positive fundamental developments. The stock shows strong revenue growth with FY2026 reaching $120 million, though profitability remains negative. Recent FDA approval for Ryoncil's potency assay and completion of Phase 3 back pain trials provide catalysts. Technical indicators show oversold conditions with RSI at 22.4, while moving averages signal bearish momentum.
Investment outlook balances high growth potential against persistent losses. The expanding Ryoncil market share and pipeline progress offer upside, but negative margins and cash burn pose risks. Analyst consensus leans bullish with 45% buy ratings, yet the stock faces execution challenges in achieving profitability amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI Malaysia ETF
EWM tracks the MSCI Malaysia Index, providing exposure to the Malaysian equity market. It offers a diversified portfolio of large and mid-sized companies across various sectors in Malaysia.
Read more on EWM →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
